Aurinia Pharmaceuticals Inc (TSE:AUP) (NASDAQ:AUPH) – Equities research analysts at Seaport Global Securities decreased their Q4 2017 earnings per share (EPS) estimates for Aurinia Pharmaceuticals in a research report issued to clients and investors on Wednesday. Seaport Global Securities analyst V. Bernardino now forecasts that the company will post earnings per share of ($0.10) for the quarter, down from their previous forecast of ($0.05). Seaport Global Securities currently has a “Buy” rating on the stock. Seaport Global Securities also issued estimates for Aurinia Pharmaceuticals’ FY2019 earnings at ($0.24) EPS and FY2020 earnings at ($0.11) EPS.

TRADEMARK VIOLATION NOTICE: “Brokers Issue Forecasts for Aurinia Pharmaceuticals Inc’s Q4 2017 Earnings (AUP)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/17/brokers-issue-forecasts-for-aurinia-pharmaceuticals-incs-q4-2017-earnings-aup.html.

Shares of Aurinia Pharmaceuticals (TSE AUP) traded down C$0.19 during trading on Friday, reaching C$6.56. The company had a trading volume of 43,216 shares, compared to its average volume of 124,022. Aurinia Pharmaceuticals has a 52-week low of C$2.75 and a 52-week high of C$14.17.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Receive News & Stock Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.